T-cell vaccine for COVID-19 may last longer than current vaccines

The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. Focusing on the T-cell instead, Penn State researchers have partnered with Evaxion Biotech on a study that is the first to demonstrate the effectiveness of an artificial intelligence-generated vaccine in a live viral challenge model. Such a vaccine may provide long-lasting immunity against future emerging variants and could be used as a model for other seasonal viral diseases like the flu.

Prediction-driven decision rules, randomized control study design and survival analysis in health care practice

Predictions are becoming more and more a part of our lives, and they are becoming increasingly useful in medical science as the science evolves. Increased understanding of disease and its treatments allows us to use predictions based on predictive biomarker signatures to optimize treatment outcomes for increasingly specific subject groups.